Menu Search
Equities

Asahi Intecc Co Ltd

6XT:DUS

Asahi Intecc Co Ltd

Actions
  • Price (EUR)15.80
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:12 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ASAHI INTECC CO., LTD. is a Japan-based company engaged in the manufacture and sale of products in the medical device field and industrial device field. The Company operates through two business segments. The Medical segment is engaged in the development, manufacture and sale of private label products and OEM products in the medical device field. The Device segment is engaged in the development, manufacture, and sale of components in the medical device field and industrial device field.

  • Revenue in JPY (TTM)110.02bn
  • Net income in JPY16.52bn
  • Incorporated1976
  • Employees9.37k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		7747:TYO since
announced		Transaction
value
Nitta MoldAnnounced14 Nov 202414 Nov 2024Announced6.74%--
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.